Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protective antigen (PA) is a critical 83 kDa protein secreted by *Bacillus anthracis*, which assembles on host cell surfaces and binds to specific cell surface receptors (ANTXR1/TEM8 and ANTXR2/CMG2). After proteolytic activation, PA oligomerizes and serves as a channel for the entry of lethal factor and edema factor, leading to cytotoxicity and the symptoms of anthrax. Because it is the only component of the anthrax toxin that interacts directly with the immune system and host cell surface, PA is a key target for vaccines and antibody therapies. Immunization with PA or its fragments stimulates protective immunity by inducing neutralizing antibodies, making it the principal antigen in anthrax vaccines.
Vaccine stimulation of adaptive immune responses (generating neutralizing antibodies). Neutralization of PA by antibodies, preventing toxin entry into host cells and subsequent cytotoxicity.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protective antigen (Bacillus anthracis) (PA).